Jacqueline Hudson
Family · Orlando, FLNPI 1114074978
Payments from drug & device makers
Across 192 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$542
- Medtronic$481
- Sanofi-aventis U.S. LLC$409
- BETA Bionics, Inc.$388
- Tandem Diabetes Care, Inc.$292
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,729100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,174 |
| Lilly USA, LLC | 26 | $542 |
| Medtronic | 13 | $481 |
| Sanofi-aventis U.S. LLC | 18 | $409 |
| BETA Bionics, Inc. | 4 | $388 |
| Tandem Diabetes Care, Inc. | 11 | $292 |
| Dexcom, Inc. | 5 | $236 |
| Abbott | 10 | $203 |
| Ascendis Pharma Endocrinology Inc | 1 | $122 |
| AbbVie | 5 | $118 |
| Amgen | 4 | $102 |
| Recordati_rare_diseases_inc. | 5 | $100 |
| IBSA Pharma Inc. | 2 | $91 |
| Radius Health, Inc. | 4 | $88 |
| Neurocrine Biosciences, Inc. | 3 | $71 |
| Bayer | 3 | $52 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Novartis | 2 | $42 |
| AstraZeneca | 2 | $32 |
| Almatica Pharma LLC | 1 | $32 |
| Ionis Pharmaceuticals, Inc. | 1 | $30 |
| Merck | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Vivus LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$1,032
- MINIMED 780G$265
- DEXCOM G6 TRANSMITTER$138
- SOLIQUA 100/33$125
- Ozempic$125
- Saxenda$122
- Yorvipath$122
- Wegovy$114
- MOUNJARO$112
How this compares
$4,729 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $208,439 |
| MounjaroTirzepatide | 92 | $144,650 |
| TrulicityDulaglutide | 76 | $136,732 |
| JardianceEmpagliflozin | 107 | $114,958 |
| FarxigaDapagliflozin Propanediol | 92 | $109,496 |
| JanuviaSitagliptin Phosphate | 83 | $90,079 |
| RybelsusSemaglutide | 14 | $35,504 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $33,409 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $26,416 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $23,745 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $22,304 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $15,063 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $13,949 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $12,674 |
| NovologInsulin Aspart | 16 | $9,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $542 | $287,598196 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,174 | $253,308152 claims |
| AstraZenecaFarxiga | $32 | $109,49692 claims |
| MerckJanuvia, Janumet Xr | $23 | $102,75397 claims |
| AbbVieSynthroid | $118 | $5,54162 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $18 | $2,951219 claims |
| Sanofi-aventis U.S. LLCLantus | $409 | $2,48512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Orlando
- Donna OrtizOrlando$417K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.